Desloratadine

證據等級: L5

預測適應症: 6 個

Desloratadine: From Antihistamine Use (Original Indication Not Recorded) to Cold Urticaria

One-Sentence Summary

Desloratadine's original indication data was not provided in this evidence pack (the drug is not currently marketed in Norway, and no license-based indication text is available), but it is documented as a second-generation, long-acting H1-antihistamine. The TxGNN model predicts it may be effective for Cold Urticaria, with 3 Phase 4 clinical trials and 7 publications currently supporting this direction.

Quick Overview

Item	Content
Original Indication	Not recorded — no Norway license data or listed original indications in this evidence pack
Predicted New Indication	Cold Urticaria
TxGNN Prediction Score	99.94%
Evidence Level	L1
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action (MOA) data from DrugBank is not available for desloratadine (flagged as a High-severity data gap). Based on the evidence provided in this pack, desloratadine is described as a long-acting, selective peripheral H1-receptor antagonist — the active metabolite of loratadine. It inhibits cold-stimulus-triggered mast cell degranulation and histamine release, which is the central pathological mechanism underlying cold urticaria.

Second-generation H1-antihistamines are already recommended as first-line therapy for cold urticaria under international guidelines (e.g., EAACI/GA²LEN/EDF), and desloratadine is one of the agents used in this class. This mechanistic link — rather than a formal comparison between a documented original indication and a new one — is what underlies the TxGNN prediction, since Norway regulatory/licensing data for this compound is not currently available (market status: Not Marketed).

Because the drug is unmarketed in Norway, no independent local indication text exists to compare against; the strength of this prediction therefore rests primarily on the clinical trial and literature evidence summarized below rather than on precedent from an approved original indication.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01444196	Phase 4	Completed	30	Dose-escalation study (5/10/20 mg) assessing the dose of desloratadine sufficient to inhibit cold urticaria symptoms
NCT00600847	Phase 4	Completed	33	Randomized, double-blind, placebo-controlled crossover study comparing 5 mg vs. 20 mg desloratadine on experimentally induced cold urticaria lesions; hypothesis that updosing (20 mg) is more effective than standard dose
NCT01940393	Phase 4	Completed	150	Evaluation of the inhibitory effect of 5 antihistamines (including desloratadine) in urticaria, including cold-induced forms

Literature Evidence

PMID	Year	Type	Journal	Key Findings
14754651	2004	RCT	J Dermatolog Treat	5 mg desloratadine for 4 days significantly inhibited ice-cube-induced cold urticaria reactions in 12 patients
19201016	2009	RCT	J Allergy Clin Immunol	High-dose desloratadine decreased wheal volume and improved cold provocation thresholds vs. standard dose in acquired cold urticaria (randomized, placebo-controlled crossover)
22242678	2012	RCT	Br J Dermatol	Randomized controlled trial of H1-antihistamine dose escalation measuring critical temperature threshold in cold urticaria
15516152	2004	Review	Drugs	Review of chronic urticaria aetiology and management, including antihistamine treatment options
19032340	2008	Review	Allergy	Review of second-generation antihistamines (ebastine) in allergic rhinitis and chronic idiopathic urticaria, contextualizing antihistamine efficacy in urticarial disease
29698807	2018	Case Series	J Allergy Clin Immunol Pract	Description of food-dependent cold urticaria as a new physical urticaria variant
38025339	2023	Case Report	Qatar Med J	Case report of cold-induced urticaria following black ant bite-induced anaphylaxis

Norway Market Information

Desloratadine is currently not marketed in Norway — no license records are available in the regulatory dataset (total authorizations: 0).

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug-interaction data were not available in this evidence pack; TFDA-equivalent labeling review is flagged as a Blocking data gap.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Three completed Phase 4 randomized/controlled trials and consistent supporting literature (including three RCTs) demonstrate a dose-dependent inhibitory effect of desloratadine on cold urticaria symptoms, meeting the L1 evidence threshold. However, the drug is not currently marketed in Norway and lacks basic safety labeling data, so guardrails are needed before proceeding.

To proceed, the following is needed:

TFDA-equivalent package insert data (warnings/contraindications) — currently a Blocking data gap
Confirmed drug-drug interaction (DDI) profile
DrugBank-sourced mechanism of action documentation to formally support the mechanistic rationale
Norway market entry/regulatory filing status, or an alternative reference market's approved indication text, to establish a documented "original indication" baseline
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.